Pfizer Acquires Metsera for $4.9B, Expanding into Obesity and Cardiometabolic Market
What You Should Know:
– Pfizer Inc. and Metsera, Inc. have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company focused on developing medicines for obesity and cardiometabolic diseases…
Continue Reading

